These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 33930347)

  • 21. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 22. A novel anti-CD47 antibody with therapeutic potential for NK/T-cell lymphoma.
    Qin L; Li Y; Zeng R; He Y; Chen X; Xiao L; Zhou H
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408088. PubMed ID: 39348228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the "Smart" exosome nanoparticle therapy.
    Wu X; Ban C; Deng W; Bao X; Tang N; Wu Y; Deng Z; Xiong J; Zhao Q
    Mol Cancer; 2024 Jul; 23(1):144. PubMed ID: 39004737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Developing a 3D B Cell Lymphoma Culture System to Model Antibody Therapy.
    Foxall R; Narang P; Glaysher B; Hub E; Teal E; Coles MC; Ashton-Key M; Beers SA; Cragg MS
    Front Immunol; 2020; 11():605231. PubMed ID: 33628205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
    Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
    Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
    Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
    EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. slan
    Vermi W; Micheletti A; Finotti G; Tecchio C; Calzetti F; Costa S; Bugatti M; Calza S; Agostinelli C; Pileri S; Balzarini P; Tucci A; Rossi G; Furlani L; Todeschini G; Zamò A; Facchetti F; Lorenzi L; Lonardi S; Cassatella MA
    Cancer Res; 2018 Jul; 78(13):3544-3559. PubMed ID: 29748373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab.
    Biedermann A; Patra-Kneuer M; Mougiakakos D; Büttner-Herold M; Mangelberger-Eberl D; Berges J; Kellner C; Altmeyer S; Bittenbring JT; Augsberger C; Ilieva-Babinsky K; Haskamp S; Beier F; Lischer C; Vera J; Lührmann A; Bertz S; Völkl S; Jacobs B; Steidl S; Mackensen A; Bruns H
    Haematologica; 2024 Dec; 109(12):3928-3940. PubMed ID: 38934068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience.
    Folkes AS; Feng M; Zain JM; Abdulla F; Rosen ST; Querfeld C
    Curr Opin Oncol; 2018 Sep; 30(5):332-337. PubMed ID: 29994903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential of the tumor‑derived extracellular vesicles carrying the miR‑125b‑5p target TNFAIP3 in reducing the sensitivity of diffuse large B cell lymphoma to rituximab.
    Zhang L; Zhou S; Zhou T; Li X; Tang J
    Int J Oncol; 2021 Jun; 58(6):. PubMed ID: 33887878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway.
    Chang S; Li B; Xie Y; Wang Y; Xu Z; Jin S; Yu D; Wang H; Lu Y; Zhang Y; Ma R; Huang C; Lai W; Wu X; Zhu W; Shi J
    Neoplasia; 2022 Jan; 24(1):50-61. PubMed ID: 34890905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
    Ok CY; Xu-Monette ZY; Tzankov A; O'Malley DP; Montes-Moreno S; Visco C; Møller MB; Dybkaer K; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Han van Krieken J; Ponzoni M; Farnen JP; Piris MA; Winter JN; Medeiros LJ; Young KH
    Cancer; 2014 Jun; 120(12):1818-29. PubMed ID: 24648050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma.
    Xiong J; Wang L; Fei XC; Jiang XF; Zheng Z; Zhao Y; Wang CF; Li B; Chen SJ; Janin A; Gale RP; Zhao WL
    Blood Cancer J; 2017 Jul; 7(7):e0. PubMed ID: 28686226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
    Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD47/SIRPα blocking enhances CD19/CD3-bispecific T cell engager antibody-mediated lysis of B cell malignancies.
    Xu L; Wang S; Li J; Li B
    Biochem Biophys Res Commun; 2019 Feb; 509(3):739-745. PubMed ID: 30611570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma.
    Suzuki S; Yokobori T; Tanaka N; Sakai M; Sano A; Inose T; Sohda M; Nakajima M; Miyazaki T; Kato H; Kuwano H
    Oncol Rep; 2012 Aug; 28(2):465-72. PubMed ID: 22641236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential.
    Ma L; Zhu M; Gai J; Li G; Chang Q; Qiao P; Cao L; Chen W; Zhang S; Wan Y
    J Nanobiotechnology; 2020 Jan; 18(1):12. PubMed ID: 31931812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
    Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
    Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
    [No Abstract]   [Full Text] [Related]  

  • 40. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
    Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
    J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.